BioWorld

Jan. 6, 2004

Repligen's Secretin Fails Autism Phase III; Subgroup Has Promise

The new year greeted Repligen Corp. with disappointing data from its Phase III trial of synthetic human secretin in autism. (BioWorld Today) Read More

Corixa Gets $11.6M Grant From Government For TLR4 Agonists

Approved Rheumatoid Arthritis Drug Trimmed Patients' Dosage In Trials Conducted Nationwide

Dynogen Teams Up With J&J Unit For Overactive Bladder Treatment

New Jersey Signs Legislation Allowing Stem Cell Research

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 22, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 22, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...